Atogepant (60 mg daily), a CGRP-targeting migraine preventive, may also help patients lose weight — and the effect is more than trivial. A post hoc analysis of a long-term extension study, presented at the American Academy of Neurology 2026 Annual Meeting and now published, found gradual but sustained weight loss in patients with migraine and a BMI of 25 or higher over 52 weeks.

Weight loss kicked in early — patients dropped an average of ~2 lbs in the first 4 weeks — and continued in a cyclical pattern of plateaus and renewed loss throughout the year. Importantly, the effect didn't appear to be driven by nausea or other GI side effects, which were transient and didn't correlate with weight change, pointing instead to possible CGRP pathway effects on appetite and metabolism.

By the Numbers:

• 279 adults with episodic or chronic migraine and BMI ≥25 were analyzed
• ~2 lbs lost on average within the first 4 weeks
• ~30% of patients lost ≥5% of baseline body weight by week 52
• ~13% lost ≥10% of baseline body weight by week 52

Why it matters: Obesity and migraine have a bidirectional relationship — excess weight worsens attacks, and migraine complicates weight management. Atogepant won't replace dedicated weight-loss therapy, but for patients managing both conditions, it could be a meaningful tiebreaker when choosing among migraine preventives.